Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Bacillus Anthracis (Anthrax)
Interventions
BIOLOGICAL

AVA

BIOLOGICAL

rPA vaccine containing alhydrogel

Trial Locations (16)

20006

Accelovance, Washington D.C.

22031

Metropolitan Research, Fairfax

24333

Carilion Medical Associates, Galax

32607

Florida Medical Research Institute, Gainesville

32935

Accelovance, Melbourne

33143

Miami Research Associates, South Miami

35802

Greater Huntsville Family Practice, PC, Huntsville

36606

Discovery Alliance, Inc., Mobile

38201

McKenzie Medical Center, McKenzie

46601

Accelovance, South Bend

60462

Accelovance, Orland Park

73112

Accelovance, Oklahoma City

73120

Lynn Health Science Institute, Oklahoma City

77024

Accelovance, Houston

79106

PharamTex Research, Inc., Amarillo

92108

Accelovance, San Diego

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

PharmAthene UK Limited

INDUSTRY

NCT00170469 - Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed | Biotech Hunter | Biotech Hunter